Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · IEX Real-Time Price · USD
4.524
+0.244 (5.70%)
At close: Apr 18, 2024, 3:56 PM
4.440
-0.084 (-1.86%)
After-hours: Apr 18, 2024, 7:06 PM EDT
Moleculin Biotech Stock Forecast
MBRX's stock price has decreased by -64.99% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Moleculin Biotech stock have an average target of 35, with a low estimate of 20 and a high estimate of 45. The average target predicts an increase of 673.65% from the current stock price of 4.52.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for MBRX stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $40 | Strong Buy | Maintains | $40 | +784.17% | Apr 12, 2024 |
| Maxim Group | Maxim Group | Strong Buy Maintains $45 → $20 | Strong Buy | Maintains | $45 → $20 | +342.09% | Mar 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +894.69% | Dec 14, 2023 |
| Roth MKM | Roth MKM | Strong Buy Maintains $240 | Strong Buy | Maintains | $240 | +5,205.04% | Apr 18, 2023 |
| Oppenheimer | Oppenheimer | Buy Reiterates $75 | Buy | Reiterates | $75 | +1,557.82% | Mar 24, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-11.77
from -15.07
EPS Next Year
-7.57
from -11.77
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 75.0M | 136.5M | 184.0M |
| Avg | n/a | n/a | 36.4M | 85.3M | 141.9M |
| Low | n/a | n/a | n/a | 36.5M | 101.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 274.7% | 115.7% |
| Avg | - | - | - | 134.2% | 66.4% |
| Low | - | - | - | 0.2% | 18.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -11.60 | -6.81 | 11.66 |
| Avg | -11.77 | -7.57 | 3.55 |
| Low | -11.79 | -8.18 | -4.05 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.